Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

943 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Alternating combination chemotherapy C-MOPP (cyclophosphamide, vincristine, procarbazine, prednisone) and ABVd (adriamycin, bleomycin, vinblastine, dacarbazine) in clinical stage II-IV Hodgkin's disease: a multicenter phase II study (JCOG 8905). The Lymphoma Study Group of the Japan Clinical Oncology Group.
Takenaka T, Mikuni C, Miura A, Sasaki T, Suzuki H, Hotta T, Hirano M, Fukuhara S, Sugiyama H, Nasu K, Dohi H, Kozuru M, Tomonaga M, Tajima K, Niimi M, Fukuda H, Mukai K, Shimoyama M. Takenaka T, et al. Jpn J Clin Oncol. 2000 Mar;30(3):146-52. doi: 10.1093/jjco/hyd036. Jpn J Clin Oncol. 2000. PMID: 10798542 Clinical Trial.
Phase III study of ranimustine, cyclophosphamide, vincristine, melphalan, and prednisolone (MCNU-COP/MP) versus modified COP/MP in multiple myeloma: a Japan clinical oncology group study, JCOG 9301.
Takenaka T, Itoh K, Suzuki T, Utsunomiya A, Matsuda S, Chou T, Sai T, Sano M, Konda S, Ohno T, Mikuni C, Deura K, Yamada T, Mizorogi F, Nagoshi H, Tomonaga M, Hotta T, Kawano K, Tsushita K, Hirano M, Shimoyama M; Lymphoma Study Group of the Japan Clinical Oncology Group. Takenaka T, et al. Int J Hematol. 2004 Feb;79(2):165-73. doi: 10.1532/ijh97.03115. Int J Hematol. 2004. PMID: 15005346 Clinical Trial.
A randomized controlled trial investigating the survival benefit of dose-intensified multidrug combination chemotherapy (LSG9) for intermediate- or high-grade non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9002.
Kinoshita T, Hotta T, Tobinai K, Kobayashi T, Ishizuka N, Tomonaga M, Sai T, Ohno Y, Kasai M, Ogura M, Mikuni C, Toki H, Sano M, Masaki Y, Ohtsu T, Matsuno Y, Takenaka T, Shirakawa S, Shimoyama M; Japan Clinical Oncology Group. Kinoshita T, et al. Among authors: takenaka t. Int J Hematol. 2004 Nov;80(4):341-50. doi: 10.1532/ijh97.04085. Int J Hematol. 2004. PMID: 15615259 Clinical Trial.
Phase II study of ABVd therapy for newly diagnosed clinical stage II-IV Hodgkin lymphoma: Japan Clinical Oncology Group study (JCOG 9305).
Ogura M, Itoh K, Kinoshita T, Fukuda H, Takenaka T, Ohtsu T, Kagami Y, Tobinai K, Okamoto M, Asaoku H, Sasaki T, Mikuni C, Hirano M, Chou T, Ohnishi K, Ohno H, Nasu K, Okabe K, Ikeda S, Nakamura S, Hotta T, Shimoyama M. Ogura M, et al. Among authors: takenaka t. Int J Hematol. 2010 Dec;92(5):713-24. doi: 10.1007/s12185-010-0712-8. Epub 2010 Nov 16. Int J Hematol. 2010. PMID: 21076995 Clinical Trial.
Alternating combination chemotherapy COP (cyclophosphamide, vincristine, prednisone) and MP (melphalan, prednisone) in multiple myeloma: a multicenter phase II study (JCOG8906). Lymphoma Study Group of the Japan Clinical Oncology Group.
Takenaka T, Shirakawa S, Mikuni C, Sai T, Shimamoto Y, Araki K, Hirano M, Miura A, Ohno Y, Ichimaru M, Hanada S, Inaba S, Konishi H, Toki H, Tajima K, Niimi M, Fukuda H, Shimoyama M. Takenaka T, et al. Jpn J Clin Oncol. 1999 Oct;29(10):485-9. doi: 10.1093/jjco/29.10.485. Jpn J Clin Oncol. 1999. PMID: 10645803 Clinical Trial.
Second primary malignancies in lymphoma patients.
Takenaka T, Konda C, Sakano T, Shimoyama M, Kitahara T, Minato K, Watanabe S. Takenaka T, et al. Jpn J Clin Oncol. 1985 Jun;15(2):443-9. Jpn J Clin Oncol. 1985. PMID: 4021122
943 results